Bank of New York Mellon Corp Makes New $3.81 Million Investment in AnaptysBio, Inc. $ANAB

Key Points

• Bank of New York Mellon initiated a $3.81 million position in AnaptysBio during the second quarter, purchasing 56,401 shares and gaining approximately 0.19% ownership.
• Analyst sentiment remains generally positive, with 11 Buy, three Hold, and one Sell rating; the stock carries a consensus “Moderate Buy” rating and an average price target of $79.85.
• ANAB opened at $56.80, compared with a 52-week range of $11.40 to $72.36, and has a market capitalization of about $1.68 billion. AnaptysBio is a clinical-stage biotechnology company developing antibody therapies for immunology and inflammatory diseases.

Bank of New York Mellon Corp bought a new stake in AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 56,401 shares of the biotechnology company's stock, valued at approximately $3,807,000. Bank of New York Mellon Corp owned approximately 0.19% of AnaptysBio as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of ANAB. Tema ETFs LLC grew its holdings in shares of AnaptysBio by 0.6% in the second quarter. Tema ETFs LLC now owns 31,270 shares of the biotechnology company's stock valued at $2,111,000 after purchasing an additional 201 shares during the period. Los Angeles Capital Management LLC raised its stake in AnaptysBio by 1.5% during the fourth quarter. Los Angeles Capital Management LLC now owns 15,101 shares of the biotechnology company's stock worth $732,000 after purchasing an additional 225 shares during the period. Larson Financial Group LLC raised its stake in AnaptysBio by 21.2% during the fourth quarter. Larson Financial Group LLC now owns 1,624 shares of the biotechnology company's stock worth $79,000 after purchasing an additional 284 shares during the period. Susquehanna Portfolio Strategies LLC boosted its holdings in AnaptysBio by 1.4% in the 4th quarter. Susquehanna Portfolio Strategies LLC now owns 35,948 shares of the biotechnology company's stock valued at $1,743,000 after purchasing an additional 500 shares during the last quarter. Finally, Smartleaf Asset Management LLC boosted its holdings in AnaptysBio by 5,864.3% in the 4th quarter. Smartleaf Asset Management LLC now owns 835 shares of the biotechnology company's stock valued at $40,000 after purchasing an additional 821 shares during the last quarter.

Wall Street Analyst Weigh In

ANAB has been the topic of several analyst reports. Leerink Partners set a $90.00 price target on shares of AnaptysBio in a research report on Friday, May 15th. Scotiabank lowered AnaptysBio to a "hold" rating and set a $70.00 price objective for the company. in a research report on Tuesday, August 25th. Wolfe Research reiterated an "outperform" rating and issued a $78.00 price objective on shares of AnaptysBio in a research report on Monday, August 31st. Weiss Ratings reissued a "sell (e+)" rating on shares of AnaptysBio in a research note on Friday, August 7th. Finally, Wall Street Zen downgraded AnaptysBio from a "strong-buy" rating to a "hold" rating in a research report on Saturday, May 16th. Eleven analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, AnaptysBio has a consensus rating of "Moderate Buy" and a consensus price target of $79.85.

AnaptysBio Stock Performance

NASDAQ:ANAB opened at $56.80 on Friday. AnaptysBio, Inc. has a fifty-two week low of $11.40 and a fifty-two week high of $72.36. The company has a 50 day moving average price of $58.18 and a 200 day moving average price of $59.19. The stock has a market capitalization of $1.68 billion, a P/E ratio of -52.59 and a beta of 0.71.

AnaptysBio Profile

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company's technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company's pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.

Want to see what other hedge funds are holding ANAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AnaptysBio, Inc. (NASDAQ:ANAB - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.